That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
The Food and Drug Administration (FDA) expects to complete its safety review of the abortion pill mifepristone by March, according to a court document filed Wednesday by the Justice Department. The FDA plans to compare mifepristone’s safety with that of surgical abortions through 10 weeks’ gestation using data from about 100,000 women who took the drug. This review follows an order by a federal judge in Louisiana for an update on the safety assessment and is part of ongoing legal challenges to telehealth provisions allowing mifepristone distribution without in-person dispensing requirements.
Written locally by qwen2.5:14b on 2026-10-08,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
The Food and Drug Administration (FDA) announced that it will complete its safety review of mifepristone, a medication used for abortion, by March. This decision came in response to a court filing made by the Justice Department on Wednesday. The FDA’s review aims to compare the safety of mifepristone with surgical abortions up to 10 weeks' gestation and will analyze data from approximately 100,000 women who have used the medication. Results are expected in mid-December, after which the agency will draft a final report by March. Since its approval in 2000, hundreds of peer-reviewed studies have confirmed mifepristone's safety and effectiveness. In 2021, the FDA temporarily allowed the drug to be dispensed without an in-person visit; this policy was finalized in 2023 but may now be reconsidered based on new data collected during the review process. The FDA’s decision comes as abortion access remains a significant concern for voters ahead of the November 3 midterm elections.
Written for “FDA Abortion Pill Review” on 2026-10-08,
grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
The article's own words the score was based on. Each is quoted
verbatim and was checked against the article text before being
stored, so you can find it in the original.
Leaning: leans left for article 64522 (high confidence, 2 verified quotes) · logged 2026-10-08
The Food and Drug Administration expects to complete its safety review of the abortion pill mifepristone in March, according to a court document the Justice Department filed Wednesday.
uncertain
Department → expect → document
In the filing, the FDA said it plans to compare mifepristone’s safety to that of surgical abortions through 10 weeks’ gestation.
asserted
it → say → gestation
Its review will measure the frequency of side effects among roughly 100,000 women who took mifepristone, it said.
asserted
it → measure → mifepristone
Results of the FDA’s review are expected in mid-December.
asserted
Results → expect → mid
From there, the agency will analyze the data and draft a final report — a process it expects to wrap up in March.
asserted
it → analyze → March
The FDA approved mifepristone in 2000, and hundreds of peer-reviewed studies have found it to be safe and effective.
asserted
it → approve → studies
The FDA temporarily eliminated a requirement to dispense mifepristone in person in 2021, then finalized the change in 2023.
asserted
FDA → eliminate → 2023
It said Wednesday that it plans to re-evaluate that decision based on the new data it collects.
asserted
it → say → data
It may weigh the views of patients, providers and pharmacists, as well as additional studies it did not consider in 2023.
uncertain
it → weigh → 2023
The review’s expected completion date falls months after the Nov. 3 midterm elections — when abortion access is among the concerns for voters.
asserted
access → expect → voters
The FDA is a defendant in a Louisiana suit challenging its telehealth provision, which has largely been responsible for preserving nationwide access to abortion since the Supreme Court overturned Roe v. Wade in 2022.
asserted
Court → challenge → 2022
Louisiana filed the case on behalf of a woman who said her boyfriend had ordered abortion pills and forced her to take them.
asserted
boyfriend → file → them
In May, a federal appeals court granted Louisiana’s request to reinstate a nationwide requirement that mifepristone be dispensed in person.
uncertain
mifepristone → grant → person
But the Supreme Court quickly blocked the decision while the case plays out.
asserted
case → block → decision
Health Secretary Robert F. Kennedy Jr. commissioned the safety review last year after a conservative think tank claimed to have found a higher rate of serious complications from mifepristone than the FDA reported.
asserted
FDA → commission → mifepristone
Several top Republicans, including Sen. Bill Cassidy of Louisiana, have also pressured the Trump administration to tighten access to the drug.
asserted
Republicans → include → drug
Researchers who study reproductive health said the think tank’s findings, which were neither peer-reviewed nor published in a medical journal, amounted to junk science.
asserted
which → study → science
A wealth of data has shown that less than 0.5% of women who take mifepristone have serious adverse reactions.
asserted
who → show → reactions
It’s unclear what conclusion the FDA, which lacks a permanent commissioner, will draw from its new study.
uncertain
which → ’ → study
President Donald Trump’s pick to lead the FDA, Dr. Heidi Overton, a White House adviser, is a fierce opponent of abortion rights, having previously described medication abortion as “dangerous to women.”
At her Senate confirmation hearing last month, Overton repeatedly sidestepped questions about mifepristone, including whether she believes the abortion pill is safe.
asserted
pill → lead → mifepristone
The Aporia
